Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
$0.22
$2.64
$3.50
$1.21B0.5729,710 shsN/A
Indivior PLC stock logo
INVVY
Indivior
$21.85
-1.8%
$21.85
$14.76
$35.50
$3.01B0.353,825 shs8,100 shs
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
$1.50
-3.8%
$1.41
$0.89
$4.29
$64.34M0.84249,053 shs79,010 shs
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$0.82
+5.3%
$0.98
$0.69
$4.99
$39.06M1.63334,523 shs1.25 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
0.00%0.00%0.00%0.00%0.00%
Indivior PLC stock logo
INVVY
Indivior
0.00%0.00%0.00%0.00%0.00%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
0.00%+9.49%+3.45%+66.67%-56.52%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
0.00%-2.34%-23.79%-14.15%-77.96%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Indivior PLC stock logo
INVVY
Indivior
N/AN/AN/AN/AN/AN/AN/AN/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
2.8166 of 5 stars
3.33.00.00.02.72.50.6
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
3.7145 of 5 stars
3.45.00.00.03.31.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
0.00
N/AN/AN/A
Indivior PLC stock logo
INVVY
Indivior
0.00
N/AN/AN/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
2.50
Moderate Buy$4.50200.00% Upside
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
2.83
Moderate Buy$7.50819.68% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
$7.51M0.00N/AN/A$0.10 per share0.00
Indivior PLC stock logo
INVVY
Indivior
$791M3.81$1.15 per share18.94$1.45 per share15.07
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
$53.48M1.20N/AN/A$3.56 per share0.42
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$5.72M6.83N/AN/A$1.67 per share0.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
-$14.54M-$0.60N/AN/AN/A-273.96%-150.49%-98.51%N/A
Indivior PLC stock logo
INVVY
Indivior
$205M$1.0520.8112.00N/AN/AN/AN/AN/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
-$84.69M-$3.010.00N/AN/AN/A-78.12%-67.11%N/A
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$75.41M-$1.390.00N/AN/AN/A-79.69%-69.13%7/30/2025 (Estimated)

Latest STTK, INVVY, ATBPD, and RPTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$0.25N/AN/AN/AN/AN/A
5/1/2025Q1 2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$0.29-$0.27+$0.02-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
N/AN/AN/AN/AN/A
Indivior PLC stock logo
INVVY
Indivior
N/AN/AN/AN/AN/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
N/AN/AN/AN/AN/A
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
N/A
5.97
5.42
Indivior PLC stock logo
INVVY
Indivior
N/AN/AN/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
N/A
7.42
7.42
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/A
9.08
9.08

Institutional Ownership

CompanyInstitutional Ownership
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
N/A
Indivior PLC stock logo
INVVY
Indivior
0.05%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
85.09%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
58.74%

Insider Ownership

CompanyInsider Ownership
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
N/A
Indivior PLC stock logo
INVVY
Indivior
N/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
11.50%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
12.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
47387.00 millionN/ANot Optionable
Indivior PLC stock logo
INVVY
Indivior
800137.88 millionN/ANot Optionable
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
18042.89 million37.96 millionOptionable
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
10047.90 million42.15 millionOptionable

Recent News About These Companies

Shattuck Labs, Inc. (STTK) - Yahoo Finance
Shattuck Labs Full Year 2024 Earnings: Misses Expectations
Shattuck Labs reports Q4 EPS (37c), consensus (32c)
H.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)
Shattuck Labs initiated with an Outperform at Leerink
H.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)
Shattuck Labs’ SL-325 shows positive results in inflammatory bowel disease

New MarketBeat Followers Over Time

Media Sentiment Over Time

Antibe Therapeutics stock logo

Antibe Therapeutics OTCMKTS:ATBPD

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Indivior stock logo

Indivior OTCMKTS:INVVY

$21.85 -0.40 (-1.82%)
As of 06/9/2023

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

Repare Therapeutics stock logo

Repare Therapeutics NASDAQ:RPTX

$1.50 -0.06 (-3.85%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.51 +0.01 (+0.67%)
As of 07/11/2025 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Shattuck Labs stock logo

Shattuck Labs NASDAQ:STTK

$0.82 +0.04 (+5.32%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$0.82 +0.01 (+0.67%)
As of 07/11/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.